N
Nigel Pluck
Researcher at Hoffmann-La Roche
Publications - 10
Citations - 3105
Nigel Pluck is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Peginterferon alfa-2a & HBeAg. The author has an hindex of 7, co-authored 10 publications receiving 3030 citations. Previous affiliations of Nigel Pluck include University of Hertfordshire.
Papers
More filters
Journal ArticleDOI
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
George K. K. Lau,Teerha Piratvisuth,Kang Xian Luo,Patrick Marcellin,Satawat Thongsawat,Graham Cooksley,Edward Gane,Michael W. Fried,Wan Cheng Chow,Seung Woon Paik,Wen Yu Chang,Thomas Berg,Robert Flisiak,Philip McCloud,Nigel Pluck +14 more
TL;DR: In patients with H beAg-positive chronic hepatitis B, peginterferon alfa-2a offers superior efficacy over lamivudine, on the basis of HBeAg seroconversion, HBV DNA suppression, and HBsAg serconversion.
Journal ArticleDOI
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
Patrick Marcellin,George K. K. Lau,Ferruccio Bonino,Patrizia Farci,Stephanos J. Hadziyannis,R. Jin,Zhi-Meng Lu,Teerha Piratvisuth,Georgios Germanidis,Cihan Yurdaydin,Moisés Diago,Selim Gürel,Ming-Yang Lai,Peter Button,Nigel Pluck +14 more
TL;DR: Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine.
Journal ArticleDOI
Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.
W. G. E. Cooksley,Teerha Piratvisuth,Shou-Dong Lee,Varocha Mahachai,You-Chen Chao,Taweesak Tanwandee,Anuchit Chutaputti,W. Yu Chang,F. E. Zahm,Nigel Pluck +9 more
TL;DR: Peginterferon α‐2a (40 kDa) is superior to conventional interferonα‐2A in the treatment of chronic hepatitis C, and this is the first report on peginterferon β‐1a ( 40 kDa) in the Treatment of CHB.
Journal ArticleDOI
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a.
Patrick Marcellin,George K. K. Lau,Stefan Zeuzem,E. Jenny Heathcote,Paul J. Pockros,K. Rajender Reddy,Teerha Piratvisuth,Patrizia Farci,Wan Cheng Chow,Jidong Jia,Woon Paik,Neil Wintfeld,Nigel Pluck +12 more
TL;DR: The safety and tolerability of peginterferon alpha‐2a in patients with CHB compares favourably with that observed in CHC patients, with a lower incidence of common interferon‐related AEs and a significantly higher incidence of depression.
Journal ArticleDOI
95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine
Patrick Marcellin,George K. K. Lau,Ferruccio Bonino,P. Farci,Stephanos J. Hadziyannis,R. Jin,Z.-M. Lu,Teerha Piratvisuth,Georgios Germanidis,Nigel Pluck +9 more